Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac739 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Maria C Magnus und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: COVID-19, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Council of Norway, European Research Council, European Union.
Abstract (Originalsprache)
Background
Pregnant women are recommended to receive coronavirus disease 2019 (COVID-19) vaccines; however, relative effectiveness of vaccination by pregnancy status is unclear.
Methods
We compared the relative effectiveness of messenger RNA (mRNA) COVID-19 vaccines according to whether women received both doses while pregnant (n = 7412), 1 dose while pregnant (n = 3538), both doses while postpartum (n = 1856), or both doses while neither pregnant nor postpartum (n = 6687). We estimated risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection starting 14 days after the second dose using Cox regression, reporting hazard ratios (HRs) and 95% confidence intervals (CIs). Second, we examined relative effectiveness of a third (booster) dose while pregnant compared to outside pregnancy. The major circulating variant during the study period was the Delta variant.
Results
Fifty-four percent of women received 2 doses of the BNT162b2 vaccine, 16% received 2 doses of the mRNA-1273 vaccine, while 30% received 1 dose of both vaccines. Compared to women who received both doses while neither pregnant nor postpartum, the adjusted HR for a positive SARS-CoV-2 polymerase chain reaction test was similar if the woman received both doses while pregnant (1.04 [95% CI, .94–1.17]), 1 dose while pregnant and 1 dose before or after pregnancy (1.03 [95% CI, .93–1.14]), or both doses while postpartum (0.99 [95% CI, .92–1.07]). The findings were similar for BNT162b2 (Pfizer-BioNTech Comirnaty) and mRNA-1273 (Moderna Spikevax), and during Delta- and Omicron-dominant periods. We observed no differences in the relative effectiveness of the booster dose according to pregnancy status.
Conclusions
We observed similar effectiveness of mRNA vaccines against SARS-CoV-2 infection among women regardless of pregnancy status at the time of vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
- Public Health Ontario, Toronto, Canada.
- ICES, Toronto, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
- Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Canada.
- Department of Family and Community Medicine, University of Toronto, Toronto, Canada.
Förderung
- Research Council of Norway
- European Research Council
- European Union
- Horizon 2020 Research and Innovation Programme
Zitieren
APA
Magnus, M. C., Håberg, S. E., Carlsen, E. Ø., Kwong, J. C., Buchan, S. A., & Fell, D. B. (2023). Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac739
Vancouver
Magnus MC, Håberg SE, Carlsen EØ, Kwong JC, Buchan SA, Fell DB. Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac739
BibTeX
@article{Magnus2023,
author = {Magnus, Maria C and Håberg, Siri E and Carlsen, Ellen Ø and Kwong, Jeffrey C and Buchan, Sarah A and Fell, Deshayne B},
title = {Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac739}
}
EUVIMED